MinXray Affirms Quality of Its Medical Devices with ISO Certification

New Market Requirements Inspire ISO13485:2016 Certification

As healthcare industries begin to require International Organization for Standardization (ISO) certification from their medical device manufacturers, MinXray Inc., a key global supplier of portable, compact digital imaging equipment, announced that it earned ISO13485:2016 Certification on April 21, 2022.

The certification ensures compliance with internationally recognized best practices and safety protocols.

ISO 13485 is a Quality Management System for medical device/component manufacturers. This includes any organization that designs, produces, installs, or services medical devices and components. As a globally recognized standard, ISO 13485:2016 makes product conformity possible amidst expanding international supply chains.

Due to the vital nature of these products, conformity is paramount for reducing risk and increasing customer satisfaction. To earn the certificate, MinXray had to demonstrate to a third-party registrar via certification audit that its quality assurance processes consistently provide devices that meet both customer requests and applicable regulatory requirements.

MinXray’s Director of Technical and Customer Support, Ed Dubbs, commented that MinXray was already doing well before the audit, saying, “We had the details and data required to document adherence to regulatory codes. The audit and subsequent certification gave us added insight into our company’s conformance.”

Moving forward, MinXray’s certification will help its business stand out and grow in the industries that require ISO compliance. MinXray continues to see development internally as well, with Dubbs stating, “The challenge now is to keep MinXray focused on what we do well while being mindful of our deeper understanding of who we are and how we can be better.”


Other diagnostic imaging news can be found here.

SourceMinXray

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”